- Current report filing (8-K)
20 Juni 2012 - 10:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of
1934
Date of Report (date of earliest event reported): June 14, 2012
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-9601
|
|
43-0618919
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2280 Schuetz Road
St. Louis, MO
|
|
|
|
63146
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
(314) 645-6600
(Registrants telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 5.08.
|
Other Events
.
|
K-V
Pharmaceutical Company (the Company) hereby announces that it has scheduled its 2012 Annual Meeting of Stockholders (the 2012 Annual Meeting) at 10:00 a.m., central daylight time, on Thursday, September 13, 2012, at a
location to be announced at a later time. Stockholders of record as of the close of business on July 16, 2012 are entitled to notice of and to vote at the 2012 Annual Meeting. The Company will be filing a proxy statement providing further
details of the 2012 Annual Meeting.
The Registrant will post this Form 8-K on its Internet website at
www.kvpharmaceutical.com. References to the Registrants website address are included in this Form 8-K only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the
Registrants website does not constitute part of this Form 8-K or the press release.
* *
*
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 20, 2012
|
|
|
K-V PHARMACEUTICAL COMPANY
|
|
|
By:
|
|
/s/ Patrick J. Christmas
|
|
|
Patrick J. Christmas
|
|
|
VP, General Counsel and Secretary
|
K V Pharma (NYSE:KV.A)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
K V Pharma (NYSE:KV.A)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über KV Pharmaceutical Co. CL A (New York Börse): 0 Nachrichtenartikel
Weitere News-Artikel